Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TOP1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TOP1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/TOP1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TOP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/TOP1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TOP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/TOP1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TOP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TOP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TOP1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TOP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TOP1 | SNV | Missense_Mutation | novel | c.1684N>A | p.Asp562Asn | p.D562N | P11387 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TOP1 | SNV | Missense_Mutation | novel | c.1919T>C | p.Phe640Ser | p.F640S | P11387 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A5-A2K4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
TOP1 | SNV | Missense_Mutation | rs754130011 | c.284N>A | p.Arg95Gln | p.R95Q | P11387 | protein_coding | tolerated_low_confidence(0.57) | possibly_damaging(0.614) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TOP1 | SNV | Missense_Mutation | novel | c.424N>A | p.Glu142Lys | p.E142K | P11387 | protein_coding | tolerated(0.36) | benign(0.017) | TCGA-AJ-A2QM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
TOP1 | SNV | Missense_Mutation | novel | c.1277N>G | p.Tyr426Cys | p.Y426C | P11387 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TOP1 | SNV | Missense_Mutation | | c.1637N>A | p.Arg546Gln | p.R546Q | P11387 | protein_coding | tolerated(0.53) | benign(0.049) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
TOP1 | SNV | Missense_Mutation | | c.76N>T | p.Asp26Tyr | p.D26Y | P11387 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.75) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TOP1 | SNV | Missense_Mutation | | c.531N>T | p.Lys177Asn | p.K177N | P11387 | protein_coding | tolerated(0.09) | benign(0.431) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TOP1 | SNV | Missense_Mutation | | c.1637N>A | p.Arg546Gln | p.R546Q | P11387 | protein_coding | tolerated(0.53) | benign(0.049) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
TOP1 | SNV | Missense_Mutation | novel | c.1118N>C | p.Leu373Pro | p.L373P | P11387 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7150 | TOP1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | SN-38 | 7-ETHYL-10-HYDROXYCAMPTOTHECIN | |
7150 | TOP1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | O-METHYLCALOTHRIXIN A | O-METHYLCALOTHRIXIN A | 19203291 |
7150 | TOP1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | 9-PHENYLIMIDAZO[1,2-H][1,7]NAPHTHYRIDINE | CHEMBL455004 | 22503207 |
7150 | TOP1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | 10-HYDROXYEVODIAMINE | CHEMBL2171812 | 22867019 |
7150 | TOP1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | TLC-388 | | |
7150 | TOP1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | SIMOCYCLINONE D8 | SIMOCYCLINONE D8 | 22867097 |
7150 | TOP1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | TOPOTECAN | TOPOTECAN | |
7150 | TOP1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | Etirinotecan pegol | | |
7150 | TOP1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | INDIMITECAN | INDIMITECAN | 20630766 |
7150 | TOP1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | LIPOTECAN | | |